Recurrent Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Directions

Area of Science:

• Hepatology
• Transplant Surgery
• Immunology

Background:

• Primary sclerosing cholangitis (PSC) is a significant indication for liver transplantation, accounting for 5-15% of global transplant recipients.
• While liver transplantation offers favorable outcomes, recurrent PSC (rPSC) is a known complication, with increasing prevalence over time post-transplant.
• Recurrent PSC negatively impacts graft survival and may necessitate retransplantation, highlighting the need for understanding its underlying mechanisms.

Purpose of the Study:

• To review the pathophysiology and identify risk factors associated with recurrent primary sclerosing cholangitis (rPSC) post-liver transplantation.
• To emphasize the diagnostic challenges of rPSC, including the importance of excluding alternative etiologies.
• To discuss the current landscape and future directions for managing rPSC, including the search for novel therapeutic targets.

Main Methods:

• This is a review article, synthesizing existing literature on recurrent PSC.
• It focuses on analyzing pretransplant recipient characteristics, inflammatory bowel disease (IBD) factors, and donor-specific and transplant-specific factors.
• Diagnostic criteria and differential diagnoses for rPSC are discussed.

Main Results:

• Recurrent PSC is associated with specific pretransplant recipient factors, IBD status, and donor/transplant characteristics.
• Accurate diagnosis of rPSC requires careful exclusion of other causes of graft dysfunction.
• No definitive cure for rPSC currently exists.

Conclusions:

• Understanding the multifaceted risk factors for rPSC is crucial for patient management and risk assessment.
• Accurate diagnosis is paramount to guide appropriate treatment strategies and patient counseling.
• Future research focusing on the natural history and risk factors of rPSC is essential for developing targeted therapies.